Quoin Pharmaceuticals' QRX003 Study Achieves Full Skin Healing In 6 Weeks, Stock Soars In Pre-Market

(RTTNews) - Quoin Pharmaceuticals, Ltd. (QNRX), Wednesday announced additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome study of QRX003.

The company noted that after six weeks of continued whole body application of QRX003, the subject's skin remains almost completely healed. Moreover, the patient has continued to have no requirement for previously necessary medications such as antibiotics, antivirals, antihistamines and glucocorticoids.

The study also demonstrated that the patient experienced almost complete elimination of pruritus or itch, zero nightly sleep disturbances without any sedating medication, and no adverse events after six weeks.

Following this, the company has received approval to initiate whole body application of QRX003 to a second pediatric Netherton patient. It is expected to commence within a few weeks.

In the pre-market hours, Quoin's stock is surging 94.92 percent, to $0.41 on the Nasdaq.